RE Dickinson Investment Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

RE Dickinson Investment Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$100	Buy	+205	New	+$151	﹤0.01%	292

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

RE Dickinson Investment Advisors's LCTX Position: Q4 2024 in Review

RE Dickinson Investment Advisors opened a new position in Lineage Cell Therapeutics (LCTX) in Q4 2024: 205 shares worth $100. The stake represents ﹤0.01% of the portfolio and ranks #292 among its holdings.

126 funds tracked by Wall St. Rank hold LCTX as of Q4 2024.

RE Dickinson Investment Advisors held 205 shares of Lineage Cell Therapeutics worth $100 as of Q4 2024.
Lineage Cell Therapeutics was a new RE Dickinson Investment Advisors position in Q4 2024.
Lineage Cell Therapeutics made up ﹤0.01% of RE Dickinson Investment Advisors's portfolio in Q4 2024, its #292 holding.
126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2024.

Based on RE Dickinson Investment Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.